Table 4.
Published studies on the use of DEX implant for retinal telangiectasia
| Reference | Study design | No of eyes | Previous treatment | Treatment | Follow-up | Retreatment | BCVA | CMT Complications |
|---|---|---|---|---|---|---|---|---|
| Sandali et al55 | Case report | 1 | 3 BEV IVT | DEX | 15 months | 2 DEX | From 20/32 to 1 month: 20/20 | From 398 μm NR to 1 month: 250 μm |
| Loutfi et al56 | Case report | 1 | 3 BEV IVT 1 IVTA |
DEX | NR | 3 DEX | From 0.3 to 0.59 logMAR: 6 weeks after 1st DEX; from 0.3 to 0.64 logMAR: 6 weeks after 2nd DEX; from 0.3 to 0.78 logMAR: 2 weeks after 3rd DEX | From 397 μm NR to 286 μm: 6 weeks after 1° DEX; 6 weeks after 2° DEX: 279 μm; 2 weeks after 3° DEX: 279 μm |
| Lei and Lam62 | Retrospective | 1 | 8 ranibizumab IVT + laser |
DEX | 17 months | 4 DEX | From 1 to 52 weeks: 0.5 logMAR |
From 607 μm NR to 52 weeks: 346 μm |
Abbreviations: BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported.